Serological identification and expression analysis of gastric cancer-associated genes

A Linē*,1, A Stengrēvics2, Z Slucka1, G Li3, Ė Jankevics1 and RC Rees3

1Biomedical Research and Study Centre, University of Latvia, 1 Ratsupites St, LV-1067, Riga, Latvia; 2Latvian Oncology Center, 4 Hipokrata St, LV-1079, Riga, Latvia; 3Department of Life Sciences, Nottingham Trent University, Clifton Lane, Nottingham NG1 1 BN, UK

Keywords: SEREX; tumour antigens; autoantibodies; TACC1; Tbdn-1; NUCB2

Serological identification of tumour antigens by recombinant expression cloning has proved to be an effective strategy for the identification of cancer-associated genes having a relevance to cancer aetiology and progression, and for defining possible targets for immunotherapeutic intervention. In the present study we applied this technique to identify immunogenic proteins for gastric cancer that resulted in isolation of 14 distinct serum-reactive antigens. In order to evaluate their role in tumourigenesis and assess the immunogenicity of the identified antigens, we characterised each cDNA clone by DNA sequence analysis, mRNA tissue distribution, comparison of mRNA levels in cancerous and adjacent non-cancerous tissues and the frequency of antibody responses in allogeneic patient and control sera. Previously unknown splice variants of TACC1 and an uncharacterised gene Ga50 were identified. The expression of a newly identified TACC1 isoform is restricted to brain and gastric cancer tissues. Comparison of mRNA levels by semi-quantitative RT–PCR revealed a relative overexpression of three genes in cancer tissues, including growth factor granulin and Tbdn-1 – an orthologue of the mouse acetyltransferase gene which is associated with blood vessel development. An unusual DNA polymorphism – a three-nucleotide deletion was found in NUCB2 cDNA but its mRNA level was consistently decreased in gastric tumours compared with that in the adjacent non-cancerous tissues. This study has revealed several new gastric cancer candidate genes; additional studies are required to gain a deeper insight into their role in the tumorigenesis and their potential as therapeutic targets.

British Journal of Cancer (2002) 86, 1824–1830. doi:10.1038/sj.bjc.6600321 www.bjcancer.com
© 2002 Cancer Research UK

Cancer development is a multistep process, during which the cell acquires new phenotypic traits (overriding growth controls, induction of angiogenesis, evasion from host anti-tumour responses, extravasation and growth at metastatic sites etc.) as a result of successive genetic alterations (Hanahan and Weinberg, 2000). Identification of genetic/epigenetic alterations that contribute to the malignant phenotype capabilities is of major importance for the understanding the molecular basis of cancer, defining possible targets for therapeutic intervention, prognosis and diagnosis of human malignancies. Sahin et al (1995) introduced a novel approach – serological identification of tumour antigens by recombinant expression cloning – called SEREX, for the identification of tumour antigens recognised by cancer patient autoantibodies. This strategy is based on the construction of cDNA expression libraries from tumour specimens and immunoscreening of the libraries with cancer patient sera, thus allowing a systematic search for immunoreactive proteins (Sahin et al, 1995). SEREX has been applied to multiple human tumours, including melanoma (Jager et al, 2000a), renal cell cancer (Scanlan et al, 1999), astrocytoma (Sahin et al, 1995), breast (Jager et al, 1999) and colon (Scanlan et al, 1998), identifying tumour antigens for each tumour type, indicating that a humoral response is elicited in the majority of cancer patients.

SEREX-defined antigens represent a broad spectrum of structurally and functionally diverse proteins – transcription factors, adhesion molecules, signalling molecules, metabolic enzymes and cDNA sequences of 1549 antigens have been deposited in the SEREX database. Several categories of antigens have been detected by SEREX i.e. shared cancer-testis (C-T) antigens, differentiation antigens, mutated genes and translocation products, splice variant products, overexpressed antigens, viral antigens, cancer-related and cancer-independent autoantigens (Tureci et al, 1997; Sahin et al, 2001). Although the majority of the SEREX-identified genes have not been characterised beyond the preliminary sequence analysis, several of them have been proposed as attractive candidates for the construction of anti-cancer vaccines. For instance, ‘cancer-testis’ antigen NY-ESO-1 was identified by SEREX in oesophageal cancer and is regarded as one of the most immunogenic tumour antigens; antibody responses to NY-ESO-1 have been observed in 40–50% of patients with NY-ESO-1 expressing tumours and antibody production strongly correlates with CD8+ T cell responses in these patients (Jager et al, 2000c). Clinical trials, investigating the immunological effects of vaccination with NY-ESO-1 peptides, are ongoing (Jager et al, 2000b). Several previously known cytotoxic T cell targets, for example tyrosinase and MAGE antigens, have been detected by SEREX, supporting the premise of integrated CTL and B cell responses to tumour antigens. Moreover, antibody responses to mutated p53 (Scanlan et al, 1998), putative tumour suppressor ING1 (Jager et al, 1999) and amplified translation factor elf-4A (Brass et al, 1997) have been detected by SEREX, thus demonstrating the potential...
of this technique for identification of genes that play a role in cancer aetiology and may serve as diagnostic markers or indicators of progression of the disease.

In the present study we applied SEREX to identify clinically relevant cancer-associated genes in human gastric carcinoma, and to define further the spectrum of immunogenic proteins in cancer. Fourteen different antigens were recognised by cancer patients’ sera and were further characterised by sequence analysis, mRNA expression pattern and reactivity with allogeneic sera.

MATERIALS AND METHODS

Tissue specimens and patient sera

Gastric cancer and the adjacent non-cancerous tissue specimens were resected and snap frozen immediately after surgery. Tissue specimens and sera were obtained from 20 gastric cancer patients who had undergone surgical resection at the Latvian Oncology Centre after the informed written consent was obtained (the study has been approved by the local ethical review board). In addition, serum samples were obtained from stomach, colon, breast and prostate cancer patients undergoing diagnostic procedures and from healthy volunteers.

Construction of cDNA expression library

A cDNA expression library was constructed from a tumour specimen of a moderately differentiated, ulcerated gastric adenocarcinoma. Total RNA was isolated using Trizol reagent according to manufacturer’s protocol (Life Technologies, Inc.). Poly(A)^+ RNA was purified from total RNA using Dynabeads mRNA Purification kit (Dynal AS, Norway) and cDNA was ligated into the lambda Uni-ZAP XR vector using Gigapack III Gold cloning kit (Stratagene GmbH). After in vitro packaging, library containing 2 x 10^6 primary cDNA clones was obtained.

Immunoscreening

Immunoscreening of cDNA library was performed as described by Sahin et al (1995). Briefly, after one round of amplification, the cDNA library was screened with 1:250 diluted autologous patient’s serum and allogeneic sera, which had been previously preabsorbed with E coli-phage lysate. In order to eliminate cDNA clones encoding human IgG, nitrocellulose membranes containing phage plaques were pre-screened with AP-conjugated rabbit anti-human IgG secondary antibody (Pierce, USA) and reactive plaques were marked to exclude them from further study. Membranes were then incubated with patients’ sera, and reactive cDNA clones were detected with AP-conjugated secondary antibody and visualised by incubating with 5-bromo-4-chloro-3-indolyl-phosphate and nitroblue tetrazolium. The reactive phage clones were subcloned to monoclonality and converted to pBluescript phage-mids.

DNA sequencing and sequence analysis

Plasmid DNA was purified using QIAprep Spin Miniprep kit (QIAGEN GmbH), analysed by EcoRI/XhoI restriction enzyme digestion and those representing different cDNA inserts were sequenced using BigDye Terminator Cycle Sequencing Ready Reaction kit on ABI PRISM 310 automatic sequencer (Applied Biosystems). Gene-specific primers were designed to obtain full insert sequences. cDNAs were identified by homology search through GenBank (www.ncbi.nlm.nih.gov). Multiple sequence alignments were performed with DNASIS (Hitachi Software Engineering Co Ltd) and MACAW (NCBI) software. Chromosomal localisation and exon–intron organisation for uncharacterised cDNAs was determined by comparison to the working draft of the human genome. Putative protein domains were predicted by scanning the sequences against PROSITE and Pfam databases (www.expasy.org and www-ludwig.unil.ch/SEREX).

Detection of antibodies in allogeneic sera

To assess frequencies of antibody responses to the SEREX-defined antigens in allogeneic sera, slightly modified immunoscreening procedure was used. E coli were transfected directly on gridded agar plate, by spotting 1 μl of monoclonal positive phage (20–30 pfu ml^-1) side by side with non-recombinant phages. ‘Phage arrays’ were screened with 1:200 diluted allogeneic sera as described above, excluding the IgG pre-screening step.

Comparative RT – PCR analysis

The mRNA expression pattern of SEREX-defined antigens was analysed by RT – PCR in a panel of normal tissue RNA from whole brain, liver, heart, kidney, lung, trachea (Clontech), spleen, colon, stomach, tests, ovary (Ambion), PBLs and a specimen of gastric cancer and adjacent tissues. Relative mRNA levels were compared between cancerous and adjacent non-cancerous tissues by semi-quantitative RT – PCR. Total RNA was isolated from paired tissue specimens using Trizol reagent according to manufacturer’s protocol (Life Technologies, Inc.). The first-strand cDNA was synthesised from 4 μg of total RNA primed with oligo-dT(18) and random hammer primers using First-Strand cDNA Synthesis Kit (Fermentas, Lithuania). Genespecific PCR primers located within different exons were designed to amplify cDNA fragments (300–400 bp in length) of nine SEREX-defined genes and GAPDH, β-actin and histone H4 were used as internal standard genes. One fifth of RT mixture was amplified in GeneAmp PCR System 2400 thermal cycler (Perkin-Elmer Corp.) in a total reaction volume of 20 μl containing 10 pmole of each primer, 200 μM of dNTPs and 2 U of Taq polymerase (Fermentas, Lithuania). Optimisation of cycling conditions (amount of input cDNA and number of cycles) was performed as described by Toh et al (1997). Amplification of all target genes was performed simultaneously, at the same cycling conditions (1 min at 94°C, 30 s at 58°C, 45 s at 72°C), except for the number of cycles that was determined for each target gene (20 for β-actin, 25 for GAPDH, 27 for Zg4, 28 for Ga35 and Ga19, 29 for Ga27, Ga50, Zg2, histone H4 and 30 for Ga34, Zg14 and Zg15). Quantitative analysis of RT – PCR products was performed densitometrically after scanning the ethidium bromide stained gel on digital gel documentation and analysis system GDS8000 (Ultra-Violet Products Ltd, UK) and the intensities of bands were calculated using GelWorks software. Standard curves of amplification of each target gene were constructed from series of PCRs with ten 1.5-fold dilutions of normal stomach cDNA. Amounts of PCR products were linearly dependent on input cDNA over 10-fold dilutions of cDNA. The relative amounts of each mRNA were normalised to GAPDH and β-actin. The obtained values in tumours (T) were compared to those in matched normal epithelium (N) and T/N ratios were calculated for each mRNA from each patient’s tissue samples. Each reaction was performed in duplicate. Ratios ≥2 or ≤0.5 (the mean values of two independent experiments) were considered to represent significant alteration of expression levels.

5’ and 3’ RACE analysis

5’ and 3’ ends of full-length cDNAs were cloned from gastric cancer and adjacent tissues using FirstChoice RLM-RACE kit (Ambion) according to manufacturer’s protocol. Briefly, for cloning of 5’-ends, 10 μg of total RNA was treated with Calf Intestinal Phosphatase to remove 5’-phosphates from un-capped
RNAs, the cap structure was removed from the full-length mRNA by Tobacco Acid Pyrophosphatase and RNA adapters were ligated to mRNA molecules containing 5’-phosphate. A random-primed reverse transcription and nested PCR with gene-specific and adapter-specific primers were performed and products were cloned using InSt/AcloneSM PCR Product Cloning Kit (Fermentas, Lithuania). For cloning of 3’ ends, 1 μg of total RNA was reverse transcribed using an oligo (dT)-anchored 3’RACE adapter and nested PCR was performed.

RESULTS

Identification of serum-reactive cDNA clones

Eleven serum-reactive clones were identified by immunoscreening of approximately $8 \times 10^5$ clones from gastric cancer cDNA expression library with autologous patient’s serum. In addition, $\sim 3 \times 10^4$ phage plaques were screened using allogeneic serum from a patient with poorly differentiated infiltrative gastric adenocarcinoma, resulting in the isolation of nine positive clones. Full insert sequences of serum-reactive cDNA clones were obtained and identified by homology search through GenBank and SEREX databases. This revealed that serum-reactive clones are derived from 14 distinct genes, including eight genes whose function is unknown (listed in Table 1). Only two genes were detected by both autologous and allogeneic screening.

The frequency of antibodies from cancer patients and controls reacting with SEREX antigens was determined. Seven of the antigens had similar reactivity with serum from cancer patients and controls had similar reactivity with serum from cancer patients and healthy individuals (Table 2).

### Table 1 Genes identified by SEREX analysis of gastric cancer

| Clone | Chr. location | Gene symbol* | NCBI reference sequence | Product, function, features, expression pattern |
|-------|---------------|--------------|-------------------------|------------------------------------------------|
| Ga19  | 4             | tbdn-1       | NM_025085               | Orthologous to mouse tbdn-1 acetyltransferase which is involved in regulation of angiogenesis. |
| Ga27  | 17q21.32      | GRN          | NM_002087               | Epithelial cell growth factor granulin. Upregulated in brain tumours and highly tumorigenic cell lines. |
| Ga34  | 4p15.33–q24   | KIAA0373     | NM_014684               | Function unknown. Ubiquitously expressed. |
| Ga44  | 5pter–q11     | Endomucin-2  | NM_016242               | Function unknown. Trans-membrane helix. |
| Ga55  | 12q12–12q14.3 | HSPC232      | NM_016488               | Arginyl-tRNA synthetase. Aminoacylation of tRNA. |
| Ga52/Zg15 | 15q22–q24 | KIAA1561     | AB004871               | Hypothetical protein. Function unknown. Multiple alternatively spliced isoforms. |
| Ga55b | 8p11          | TACC1        | NM_006283               | Uveal auto-antigen; similar to dog’s C3VS protein, which is upregulated in thyroid by TSH stimulation. |
| Ga71  | 3q28          | FXR1         | NM_005087               | Fragile X mental retardation-related protein 1. Auto-antibodies are found in several auto-immune diseases. |
| Zg2   | 15            | KIAA0295     | AB0002293               | Function unknown. Zinc finger C2H2 motif. Ubiquitously expressed. |
| Zg4   | 1p15.1–p14    | NUCB2        | NM_005013               | Ca2+ binding protein. Contains DNA binding domain, helix–loop–helix motif, acidic amino acid region, leucine zipper and EF-hands. |
| Zg6   | 12            | KIAA1245     | AB0282990              | Partially similar to hypothetical protein KIAA1164. |
| Zg10  | 1p15          | SWAP-70      | AB014540               | Function unknown. Ubiquitously expressed. |
| Zg14  | 22q13.2–13.31 | CGI-96       | NM_015703               | Involved in Ig heavy chain class switching. Expressed predominantly in B lymphocytes. |

*HUGO approved gene symbols were used when available. These cDNA sequences have been deposited in the GenBank (see text for accession numbers). According to RT–PCR data at the Kazusa DNA Research Institute web-site (www.kazusa.or.jp).

Analysis of sequence variations

Several sequence variations were found in three cancer-derived cDNAs in comparison with GenBank entries. An alteration of codon GAC (nt394) to GCC (Asp→Gly) in clone Ga34 (deposited in GenBank, AY039241) encoding Endomucin2 (NM_016242) and three scattered nucleotide insertions within the 136 bp region of Zg14 (deposited in GenBank, AY039240) encoding for CGI-96 (AF151854), resulting in an altered 45 amino acid region in the predicted protein sequence were also observed. However sequen-
Direct sequencing of NUCB2 cDNA derived from cancerous tissue of the patient whose serum was used for allogeneic screening showed heterogeneity of RT–PCR products at the 3' end of the coding region which is not present in the clone Zg4. The RT–PCR product was cloned into pTZ57R/T vector and two of five clones sequenced had ACA deletion (submitted to GenBank, AF450266). The 3-nucleotide deletion was also demonstrated by sequencing of amplified genomic DNA fragment. As the normal tissue sample from this patient was not available we could not directly determine whether this deletion represent somatic mutation or allelic polymorphism. Next we analysed DNA sequences from tumour and adjacent tissue samples of five gastric cancer patients, tumour and blood samples of five breast cancer patients and from blood samples of 25 donors. All paired tissue specimen had the same genotype thus showing that the deletion represents a germline DNA polymorphism and likely is not an immunogenic stimula for production of anti-NUCB2 antibodies in the patients. Nevertheless, all gastric cancer patients and two breast cancer patients were heterozygous, one breast cancer patient had ACA deletion on both alleles, however five of 25 donors were also heterozygous at this locus, thus showing very high frequency of this unusual polymorphism not only among cancer patients but also in a general population.

**Identification of TACC1 and HSPC232 splice variants**

Comparison of Ga55 cDNA (submitted to GenBank, AY039239) with the published TACC1 sequence (GenBank, AF048910) showed that Ga55 represents a TACC1 isoform generated by inclusion of alternative 36 bp exon. The alternative exon is present in another GenBank sequence (KIAA1103, AB029026) derived from brain tissue, but is skipped in all other EST sequences, indicating that TACC1 pre-mRNA splicing may be regulated in tissue specific manner. The mRNA expression pattern of TACC1 isoforms was analysed by RT–PCR in a panel of RNAs derived from normal brain, liver, heart, kidney, lung, trachea, spleen, colon, stomach, testis, ovary, PBLS and in gastric cancer and adjacent non-cancerous tissue specimens using primers flanking the alternative exon. The transcript variant lacking the alternative exon was detected universally in all tissues tested. In contrast, the transcript containing the 36 bp exon was strongly expressed in brain and gastric cancer tissues; just trace amounts were detectable in lung and colon, but not in normal stomach and other normal tissues analysed (Figure 1). In subsequent analysis of paired gastric cancer and normal tissues, inclusion of the alternative exon was detected in three of 20 cancer tissue specimens but not in the adjacent tissues.

Clone Ga50 represents a novel splice variant of uncharacterised gene HSPC232. Alignment of GenBank cDNA entries and corresponding ESTs revealed at least four transcript variants differing in their 5' and 3' regions. RLM–RACE analysis showed that all splice variants are expressed in gastric cancer and adjacent tissues, and no additional variants were found. RT–PCR analysis showed that the splice variants are universally expressed in normal tissues but the efficiency of alternative splicing seems to be differentially regulated in different tissues. However no significant differences in expression of the splice variants in gastric cancer and adjacent tissues were found.

**mRNA expression pattern of SEREX-identified antigens**

Multiple matching EST sequences were found in GenBank/EMBL databases for all of the identified antigens, however some genes shared sequence identity only to ESTs derived from cancerous tissues. Therefore, we analysed the mRNA tissue distribution of selected antigens by RT–PCR in normal tissues (brain, liver, heart, trachea, lung, kidney, spleen, colon, stomach, testis, ovary and PBLS) and in gastric cancer and adjacent epithelium. Ga19, Zg15 and Zg4 mRNAs showed differential tissue distribution pattern. Relatively high expression of Ga19 and Zg15 was observed in normal testis, ovary, spleen, stomach, colon, and gastric cancer while it was weak or undetectable in other tissues tested. Zg4 was predominantly expressed in spleen, testis and normal stomach whereas RT–PCR signals were faint in all other tissues including cancerous and adjacent non-cancerous tissues from a gastric cancer patient (Figure 1).

**Comparison of mRNA levels in cancerous and adjacent normal tissues**

In order to evaluate whether expression levels of genes encoding SEREX-antigens are altered in cancer tissues, we compared the relative mRNA levels in cancerous and paired non-cancerous tissues by semi-quantitative RT–PCR. Expression levels of nine genes isolated from gastric cancer cDNA library (Ga19, Ga27, Ga34, Ga50, Ga55, Zg2, Zg4, Zg14, and Zg15) were analysed in paired tissue samples from 20 gastric cancer patients. Relative mRNA levels of target genes were normalised to GAPDH cDNA was amplified as an internal control. 32, 29, 27, and 25 cycles of amplification were used for Ga55, Ga19, Zg4 and GAPDH, respectively. Ga Ca 3T and Ga Ca 3N – tumour and adjacent tissues from gastric cancer patient.
Comparison of Ga19, Zg4 and Zg15 mRNA levels in three paired gastric cancer (T) and adjacent epithelium (N) samples by semi-quantitative RT–PCR. The same primers as shown in Figure 1 were used for amplification of Ga19 and Zg4. Primers used for Zg15 were: forward primer 5'-TCTGGACACTATCTTACCCAG-3', reverse 5'-GGTGGACGCTCTGACAAAG-3'. GAPDH and β-actin are used as internal standards. Histone H4 is used as a marker for the rate of cell proliferation.

Sequence analysis of Ga19 cDNA

Sequence analysis of the Ga19 clone showed an uninterrupted ORF throughout the insert sequence indicating that the cDNA represented by this clone is truncated at both 5' and 3'-ends. To obtain the complete cDNA sequence RLM-RACE was performed. A single fragment of 930 bp was obtained in 5' RLM–RACE analysis and no variation of the transcription start site was found, but the 3' RACE yielded an 850 bp product. The assembled cDNA sequence contains 281 bp 5' UTR with several stop codons, 2595 bp coding sequence and 206 bp 3' UTR (deposited in GenBank, AY039242). Scanning of the predicted amino acid sequence against PROSITE and Pfam databases revealed N-terminal acetyltransferase domain, two helix–loop–helix motifs, EF-hands and leucine zipper (Barnikol-Watanabe et al, 1994; Kroll et al, 1999). It interacts with the postmitotic growth suppressor necdin and is proposed to be involved in the regulation of survival and death of postmitotic cells by controlling Ca²⁺ homeostasis in the cytoplasm (Taniguchi et al, 2000). Taken together, NUCB2 shows some characteristics of tumour suppressor gene but further studies investigating the functional significance of the 3'-nucleotide deletion and downregulation of NUCB2 expression are required.

DISCUSSION

Definition of all immunogenic proteins in cancer (‘cancer immunome’) is regarded as the main long-term goal of SEREX (Jager et al, 1999; Pirruenko, 2000). Four of 14 antigens identified in the current study have been previously detected by SEREX in various tumour types (Table 3), and two of the identified genes – epithelial cell growth factor granulin (Lu and Serrero, 2000; Liu et al, 2000) and transforming coiled coil containing gene TACC1 (Still et al, 1999) have been previously shown to be associated with cancer. A further gene – FXR1 is an autoantigen known to elicit antibody production in scleroderma patients (Bolivar et al, 1998). Another isolated gene is an Agr-tRNA synthetase. Autoantibodies against particular aminoacyl-tRNA synthetases are frequently found in myositis, interstitial lung disease, and arthritis (Hirakata et al, 1999) and various tRNA synthetases also have been detected by SEREX in renal (Scanlan et al, 1999), breast (Jager et al, 1999) and prostate cancer, and T cell leukemia (Itoh et al, 1999). No evidence for the implication of the genes in cancer or autoimmune states has been reported for the remaining antigens.

One possible reason for the immunogenicity of self-proteins is structural changes, resulting from mutations, translocations or the experiment of splice variants. Although we identified several sequence variations in three tumour-derived cDNAs (NUCB2, endomucin-2 and CGI-96), analysis of these sequences in tumour and normal tissue specimens indicates that these variations represent allelic polymorphisms and are not likely to be associated with the immunogenicity of these proteins. Nevertheless, three-nucleotide deletion within the coding region of NUCB2 that we detected with very high frequency among the cancer patients, is very interesting finding. As a result of the deletion Glh is omitted from the hydrophobic C-terminus of the protein. Moreover, comparison of mRNA levels between cancerous and adjacent non-cancerous tissues by RT–PCR showed that the expression of NUCB2 is downregulated in 50% of gastric tumours. NUCB2 is a Ca²⁺ binding protein, which also contains putative DNA binding domain, two helix–loop–helix motifs, EF-hands and leucine zipper (Barnikol-Watanabe et al, 1994; Kroll et al, 1999). It interacts with the postmitotic growth suppressor necdin and is proposed to be involved in the regulation of survival and death of postmitotic cells by controlling Ca²⁺ homeostasis in the cytoplasm (Taniguchi et al, 2000). Taken together, NUCB2 shows some characteristics of tumour suppressor gene but further studies investigating the functional significance of the 3'-nucleotide deletion and downregulation of NUCB2 expression are required.

Alterations in the pattern and efficiency of alternative splicing of several pre-mRNAs (e.g. CD44, BRCA1, WT-1) have been implicated in tumorigenesis and correlate with tumour progression (Cheng and Dougherty, 1999). Such changes may lead to altered splicing events, resulting from mutations, translocations or splice site selection may serve as an additional mechanism for the generation of protein diversity contributing to the selection of more aggressive tumour cells (Cooper and Mattox, 1997; Philips and Cooper, 2000). We identified several previously unknown splice variants of two genes – TACC1 represented by clone Ga55, and uncharacterised gene HSPC232 represented by clone Ga50. TACC1 is a recently identified gene, a member of TACC protein family that is involved in the regulation of interaction between centrosomes and microtubules (Gergely et al, 2000a). Overexpression of TACC1 in mouse fibroblasts results in cellular transformation and anchorage independent growth (Still et al, 1999). In Drosophila embryos, overexpression of TACC domain led to accumulation of microtubule asters and a complete failure in development of the embryos (Lee et al, 2001). In contrast, embryos carrying a mutation in d-tacc gene that decrease the level of D-TACC protein have shorter centrosomal microtubules and they also develop severe mitotic defects (Gergely et al, 2000b). These data show that perturbation of TACC gene expression may provoke various effects ranging from a genetic instability and missegregation of chromosomes to cell death. In the current study we identified a novel TACC1 isoform generated by inclusion of an alternative 36 bp exon. This isoform was strongly expressed in

Table 3  Antigens overlapping with previous SEREX analyses

| Antigen   | Tissue                      |
|-----------|-----------------------------|
| TACC1     | Stomach cancer (47)         |
| SWAP70 (KIA0640) | Renal cell carcinoma (699,338), Hodgkin's disease (765) |
| KIAA1561  | Esophageal cancer (1558), breast carcinoma (1100), hepatocellular carcinoma |
| KIAA0373  | Testis/CTCL sera (2019)     |

SEREX database ID is shown in brackets.
three of 20 specimens of gastric cancer tissues while it was unde-
tectable in the adjacent gastric epithelium and normal stomach epithelium. From normal adult tissues it was predominately
expressed in brain. We propose that alteration in the pattern of TACC1 mRNA splicing in cancer cells might lead to perturbation of TACC1 function. Whether the ectopic expression of this isoform served as a stimulus for antibody production in the patient also remains to be established. Interestingly, TACC1 and TACC2 have also been detected by SEREX in gastric cancer by Yuichi Obata (SEREX database).

The largest category of SEREX antigens occur as overexpressed
gene products. Gene amplification, elevated transcription and stability of mRNA or protein may lead to accumulation of protein and induction of immune response by exceeding the number of triggered TCRs required for T cell activation (Viola and Lanzavec-
chia, 1996; Lanzavecchia et al., 1999). In order to search for overexpressed antigens, we used semi-quantitative RT–PCR to examine the mRNA levels of the identified antigens in gastric cancer and adjacent non-cancerous tissues. Relative overexpression of Ga27 (granulin), Zg15 (orthologous of dog’s C3VS gene) and Ga19 (orthologous to mouse Tbdn-1 gene) in gastric cancer was observed. Uregulation of the growth factor granulin has been shown in brain tumours (Liu et al., 2000) and in highly tumouri-
genic cell lines (Zhang and Serrero, 1998). Granulin has been shown to have mitogenic activity in fibroblasts, epithelial cells and glioblastoma cell lines (Xu et al., 1998; Liu et al., 2000; Lu and Serrero, 2000). Zg15 represents a human orthologue of dog’s C3VS gene, its function is unknown but it is upregulated by mito-
genic stimulation in thyroid cells (Wilkin et al., 1996). Thus, increased proliferation of tumour cells alone could account for the overexpression of Zg15 in cancerous tissues. In theory, it could be considered as a proliferation marker and its prognostic signifi-
cance remains to be determined. Another gene that we found to be upregulated in three of 20 gastric cancer specimens is human orthologue of the mouse tbdn-1 gene encoding putative acetyl-
transferase. The levels and tissue distribution of tbdn-1 suggest that it may be involved in regulation of vascular and hematopoietic development and angiogenesis. Tbdn-1 is expressed at high levels at day 8 of gestation, when yolk sac vasculogenesis and blood island formation is peaking but downregulated at day 10 when formation of larger coalesced vitelline vessels occurs. In adult mouse it is expressed in perithelial endothelium, bone marrow and ovarian follicles only (Gendron et al., 2000). Although we observed relatively high expression of Tbdn-1 in spleen, colon, stomach, testis and ovary, it could be of interest to investigate which cell populations within a tumour overexpress it and whether this acetyltransferase has a role in tumour neovascularisation.

In conclusion, a number of the antigens that we have identified in this study may have a functional role in cancer aetiology or progression, and the altered expression pattern of these genes may provide the immunogenic stimuli in these patients. However other possibilities, for example, unidentified mutations or altered sub-cellular localisation which have been recently shown for β-
actin in apoptotic breast cancer cells (Hansen et al., 2001), cannot be excluded. Further studies will be focused on exploration of the possible functional differences between TACC1 isoforms, definition of cell populations that express Tbdn-1 acetyltransferase and inves-
tigation of its possible role in tumour angiogenesis. It will also be of interest to elucidate the possible role of NUCB2 in tumour progression and the functional significance of the peculiar thre-
nucleotide polymorphism. In addition, serological responses to seven antigens (including TACC1, NUCB2, Tbdn-1 and granulin etc.) were restricted to cancer patients and investigation of their relevance for sero-diagnosis or prognosis is in progress.

ACKNOWLEDGEMENTS

We thank Dr O Tureci and Dr U Sahin for helping us to establish the SEREX technique in our laboratories; Prof E Grens and Dr S Mian for motivating discussions. This work was supported by grants from Latvian Council of Science (No.2-2-011.1 and 01.0226), an UNESCO UVO-ROSTE grant, The John and Lucille
Van Geest Foundation and The Cancer and Polio Research Fund. Data deposition: cDNA sequences reported in this study have been deposited in the GenBank (accession numbers AY039238–
AY039242 and AF450266).

REFERENCES

Barnikol-Watanabe S, Gross NA, Gotz H, Henkel T, Karabinos A, Kritzin H, Barnikol HU, Hilschmann N (1994) Human protein NEFA, a novel DNA binding/EF-hand/leucine zipper protein. Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Biochim Biophys Acta 1275: 497 – 512

Bolivar J, Guelman S, Iglesias C, Ortiz M, Valdivia MM (1998) The fragile-X-
mutation: mechanisms and clinical relevance. Annual Review of Genomics and Human Genetics 1: 33 – 39

Cooper DL, Dougherty GF (1995) To metastasize or not? Selection of CD44 splice sites. Nat Med 1: 635 – 637

Cooper TA, Mattox W (1997) The regulation of splice-site selection, and its role in human disease. Am J Hum Genet 61: 259 – 266

Gendron RL, Adams LC, Paradis H (2000) Tubedown-1, a novel acetyltrans-
ferase: an autoantigen frequently eliciting humoral immune response in patients with adult T cell leukemia. Int J Oncol 14: 703 – 708

Jager D, Stockert E, Jager G, Gereau RO, Scanlan MJ, Knuth A, Old LJ, Chen YT (2000a) Serological cloning of a melanocyte rab guanosine 5'-triphosphate-binding protein and a chromosome condensation protein from a melanoma complement DNA library. Cancer Res 60: 3584 – 3591

Jager D, Stockert E, Scanlan MJ, Gereau RO, Jager E, Knuth A, Old LJ, Chen YT (1999) Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 trans-
scripts and a homologue gene. Cancer Res 59: 6197 – 6204

Jager E, Gujicic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A (2000b) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-
ESO-1+ cancers. Proc Natl Acad Sci USA 97: 12198 – 12203

Hansen MH, Nielsen H, Ditzel HJ (2001) The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 98: 12659 – 12664

Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, Akizuki M, Targoff IN (1999) Anti-KS: identification of autoantibodies to asparagi-
nyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 163: 2315 – 2320

Itoh M, Watanabe M, Yamada Y, Furukawa K, Taniguchi M, Hata T, Schmitt M, Ikeda H, Yamaguchi M, Ohno T, Nakashima K, Shiku H (1999) HUB1 is an autoantigen frequently eliciting humoral immune response in patients with adult T cell leukemia. Int J Oncol 14: 703 – 708

Jager D, Stockert E, Jager G, Gereau RO, Scanlan MJ, Knuth A, Old LJ, Chen YT (2000a) Serological cloning of a melanocyte rab guanosine 5'-triphosphate-binding protein and a chromosome condensation protein from a melanoma complement DNA library. Cancer Res 60: 3584 – 3591

Jager D, Stockert E, Scanlan MJ, Gereau RO, Jager E, Knuth A, Old LJ, Chen YT (1999) Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 trans-
scripts and a homologue gene. Cancer Res 59: 6197 – 6204

Jager E, Gujicic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A (2000b) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-
ESO-1+ cancers. Proc Natl Acad Sci USA 97: 12198 – 12203

SEREX analysis of gastric cancer antigens
A Liné et al

© 2002 Cancer Research UK
British Journal of Cancer (2002) 86(11), 1824 – 1830
Jager E, Nagata Y, Gnajtic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Junghuth A, Jager D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ, Knuth A (2000c) Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97: 4760–4765

Kroll KA, Otte S, Hirschfeld G, Barnikol-Watanabe S, Gotz H, Sternbach H, Kratzin HD, Barnikol HU, Hilschmann N (1999) Heterologous overexpression of human NEFA and studies on the two EF-hand calcium-binding sites. Biochem Biophys Res Commun 260: 1–8

Lanzavecchia A, Lezzi G, Viola A (1999) From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell 96: 1–4

Lee MJ, Gergely F, Jefferis K, Peak-Chew SY, Raff JW (2001) Msps/XMAP215 interacts with the centrosomal protein D-TACC to regulate microtubule behaviour. Nat Cell Biol 3: 643–649

Liu LM, Lallone RL, Seitz RS, Buznikov A, Gregg JP, Kornblum HI, Nelson SF, Bronstein JM (2000) Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. Cancer Res 60: 1553–1560

Liu HX, Cartegni L, Zhang MQ, Krainer AR (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27: 55–58

Lu R, Serrero G (2000) Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468. Proc Natl Acad Sci USA 97: 3993–3998

Pfreundschuh M (2000) Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer Res 60: 1553–1560

Still IH, Hamilton M, Vince P, Wolfman A, Cowell JK (1999) Cloning of TACCI, an embryonically expressed, potentially transforming coiled coil containing gene, from the 8p11 breast cancer amplicon. Oncogene 18: 4032–4038

Taniguchi N, Taniura H, Niinobe M, Takayama C, Tominaga-Yoshio K, Ogura A, Yoshikawa K (2000) The postmitotic growth suppressor neclin interacts with a calcium-binding protein (NEFA) in neuronal cytoplasm. J Biol Chem 275: 31674–31681

Thellin O, Zorez W, Lakaye B, De Borman B, Coumans B, Hennen G, Grisar T, Igout A, Heinen E (1999) Housekeeping genes as internal standards: use and limits. J Biotechnol 75: 291–295

Tureci O, Sahin U, Serrero G (1998) Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer 74: 459–463

Tureci O, Sahin U, Pfreundschuh M (1997) Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 3: 342–349

Viola A, Lanzavecchia A (1996) T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104–106

Weisinger G, Gavish M, Mazurika C, Zinder O (1999) Transcription of actin, cyclophilin and glyceraldehyde phosphate dehydrogenase genes: tissue- and treatment-specificity. Biochim Biophys Acta 1446: 225–232

Wilkin F, Savonet V, Radulescu A, Petermans J, Dumont JE, Maenhaut C (1996) Identification and characterization of novel genes modulated in the thyroid of dogs treated with methimazole and propylthiouracil. J Biol Chem 271: 28451–28457

Zanocco-Marani T, Baserga R (1998) The granulin/epithelin precursor abrogates the requirement for the insulin-like growth factor I receptor for growth in vitro. J Biol Chem 273: 20078–20083

Zhang H, Serrero G (1998) Inhibition of tumorigenicity of the teratoma PC cell line by transfection with antisense cDNA for PC cell-derived growth factor (PCDGF, epithelin/granulin precursor). Proc Natl Acad Sci USA 95: 14202–14207

Zhong H, Simons JW (1999) Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun 259: 523–526

Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT, Old LJ (1999) Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 83: 456–464

Lee MJ, Gergely F, Jefferis K, Peak-Chew SY, Raff JW (2001) Msps/XMAP215 interacts with the centrosomal protein D-TACC to regulate microtubule behaviour. Nat Cell Biol 3: 643–649

Liu LM, Lallone RL, Seitz RS, Buznikov A, Gregg JP, Kornblum HI, Nelson SF, Bronstein JM (2000) Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. Cancer Res 60: 1553–1560

Sahin U, Li G, Tureci O, Pfreundschuh M (2001) Recognition of human tumors: SEREX expression cloning to identify tumour antigens. In Cancer Immunology, Robins RA, Rees RC (eds) pp 45–57. Dordrecht/Boston/London: Kluwer Academic Publishers

Sahin U, Tureci O, Schmidt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schoertl I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92: 11810–11813

Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Tureci O, Sahin U, Pfreundschuh M, Old LJ (1998) Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 76: 652–658